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Abstract 
Biased ligands represent a new strategy for the development of more effective and better 
tolerated drugs.  To date there has been a paucity of research exploring the potential of 
ligands that exhibit either G protein or β–arrestin pathway selectivity at the endothelin 
receptors. Re-analysis of existing data may allow researchers to determine whether there is 
existing evidence that the endogenous ET peptides or currently available agonists and 
antagonists exhibit pathway bias in a particular physiological or disease setting and this is 
explored in the review.  An alternative to molecules that bind at the orthosteric site of the ET 
receptors are cell penetrating peptides that interact with a segment of an intracellular loop of 
the receptor to modify signalling behaviour.  One such peptide IC2B has been shown to have 
efficacy in a model of pulmonary arterial hypertension.  Finally, understanding the molecular 
pathways that contribute to disease is critical to determining whether biased ligands will 
provide clinical benefit.  The role of ETA signalling in ovarian cancer has been delineated in 
some detail and this has led to the suggestion that the development of ETA G protein biased 
agonists or β-arrestin biased antagonists should be explored. 
 
Graphical Abstract: Pathway bias at the ET receptors 
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Introduction 
Our understanding of how ligands interact with G protein coupled receptors is evolving, 
particularly the recognition that some have the ability to preferentially activate a subset of 
intracellular signalling cascades– so called pathway biased ligands [1].  Additionally, it is 
now accepted that recruitment of β-arrestin that occurs following activation of the majority of 
GPCRs not only results in receptor desensitisation and subsequent internalisation but may 
also contribute to cellular responses involved in normal physiology and disease such as cell 
migration and proliferation [2].  Therefore, exploiting ligand bias is likely to lead to the 
development of more effective and better tolerated medicines.  This has so far been most 
clearly demonstrated for the μ opioid receptor where the agonist TRV130, a molecule that 
discriminates between beneficial analgesia and detrimental adverse effects such as respiratory 
depression and nausea, exhibited an improved therapeutic profile compared to morphine in a 
randomized, double-blind, placebo-controlled, crossover study in healthy volunteers [3].  
Whereas bias has been considered a property of synthetic ligands it has recently been 
reported that for example endogenous opioids also show bias at the μ-opioid receptor [4] 
indicating that the presence of multiple ligands for a receptor, rather than simply representing 
physiological redundancy, may allow for nuanced cell specific signalling.  Distinct roles for 
the three endogenous endothelin (ET) peptides are emerging in development and in, for 
example, ovarian physiology but whether pathway bias may contribute to the physiology and 
pathophysiology of the endogenous peptides in the ET system has not been explored.  In 
contrast the potential for targeting the endothelin receptors with synthetic biased ligands is 
starting to be considered.  This brief review discusses current research on biased signalling at 
the ET receptors and therapeutic areas of interest. 
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ET receptors and probe dependence 
Some of the pharmacology of the endothelin receptors has over the last 20 years been 
described as atypical; not conforming to the basic tenets of receptor pharmacology.  
Particularly, this has been in differences in the behaviour of the endogenous peptides and 
synthetic agonists with respect to reversal by washout or blockade/reversal of responses by 
antagonists in in vitro studies [5, 6].  It is now apparent that for a particular receptor multiple 
active conformations, rather than just one, are possible and ligands can stabilize different 
conformations of a receptor that may activate subsets of available down-stream pathways.  
Therefore, some of the atypical pharmacology reported for ET receptors may be consistent 
with these agonists showing a degree of functional selectivity, although differences in ligand-
receptor kinetics may also contribute to these observations.  Additionally, because of the 
allosteric nature of the interaction of ligand–GPCR–intracellular protein (e.g. G protein) 
affinity measured in binding assays may differ from affinity measured in functional assays, 
specifically if different agonists stabilize particular receptor conformations then this allows 
the potential for orthosteric antagonists to demonstrate agonist specific functional affinities – 
consistent with previously reported atypical pharmacology of probe dependence [7]. 
 
Calculating ligand bias for the endogenous ET peptides and related sarafotoxin 6b at 
the ETA receptor 
There has been at least one report in vitro that ET peptides exhibit bias at the ETA receptor 
with ET-1 and ET-2 suggested to elicit their long lasting constrictor responses via different 
mechanisms that was also vascular bed dependent [8].  We have previously published data on 
both the potency and efficacy of endothelin peptides and sarafotoxins as constrictors of 
human saphenous vein [9] and in β-arrestin recruitment assays [10].  These data highlighted 
differences in the relative potencies and efficacies of these agonists in the ETA mediated 
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constrictor and β-arrestin recruitment assays indicative of bias.  Several methods for 
determining pathway bias from such data have been reported including determination of 
transducer coefficients τ/KA, as described by van Westhuizen and colleagues [11].  We have 
applied this method to our existing data to determine whether the endogenous ET peptides 
and related sarafotoxin 6b (S6b) show any evidence of bias in the G protein dependent 
vasoconstrictor assay and G protein independent β-arrestin recruitment assay.  Determining 
bias requires designation of a reference compound that is preferably the endogenous ligand.  
For the cardiovascular ETA receptor the most appropriate reference ligand is ET-1.  All data 
are expressed as a % of the maximum ET-1 response and analysed as described [10], to 
obtain values of log10(τ/KA) that are used for subsequent determination of bias factors.  
Figure 1 shows that whilst ET-1, ET-2 and S6b are full agonists in the constrictor assay (the 
ET-3 curve is incomplete at the maximum possible bath concentration) ET-3 and S6b are 
both partial agonists in the β-arrestin assay.  
 
Figure 1.  Concentration response curves to ET-1 (), ET-2 (), ET-3 () and S6b () in 
(A) the human endothelium-denuded saphenous vein and (B) an ETA-mediated β-arrestin 
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recruitment assay.  Data are expressed as a percent of the maximum response of ET-1 in each 
assay and data points are the mean±s.e.m. of 3-13 experiments. 
Compared to ET-1, all agonists tested showed a 2-4 fold bias for the G protein constrictor 
assay compared to the β-arrestin assay (Table 1).  This preliminary analysis indicated that at 
least modest pathway bias for endogenous ET peptides is possible, however the physiological 
significance of this, if any, requires more comprehensive analysis of data for ET-1, ET-2 and 
ET-3 in a broader range of relevant pathway specific assays. 
 
Table 1.  Bias analysis for the relative effectiveness of endothelin peptides in the human 
saphenous vein constrictor and ETA-mediated β-arrestin recruitment assays. 
R= (τ/KA), the transducer coefficient, where τ is an index of agonist efficacy and KA is 
functional affinity of the agonist.  ΔLogR is the relative LogR values of test agonists 
compared to the reference agonist in a particular assay.  ΔΔLogR is the relative ΔLogR 
values for particular agonists between assays. The bias factor is determined as 10
ΔΔLogR
.  
Analysis performed as described by van der Westhuizen and colleagues [11]. 
 
Ligand Bias at the ETB receptor 
There are currently no published data exploring biased agonism at the ETB receptor.  There 
are a number of ETB agonists available for study including the endogenous peptide ET-3 and 
 Saphenous Vein Constrictor 
Assay 
-Arrestin Recruitment Assay Saphenous Vein vs β-
Arrestin 
 LogR ΔLogR RE LogR ΔLogR RE ΔΔLogR Bias 
Factor 
ET-1 8.550.15 00.22 1 9.460.08 00.11 1 00.24 1 
ET-2 8.260.21 -0.290.26 0.51 8.670.03 -0.790.08 0.16 0.490.27 3.1 
ET-3 6.800.37 -1.750.40 0.018 7.110.03 -2.350.08 0.0045 0.600.41 4.0 
S6b 8.110.12 -0.440.12 0.36 8.680.06 -0.780.10 0.17 0.340.15 2.2 
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related sarafotoxin 6c (S6c) in addition to peptide agonists such as BQ3020 and IRL 1620.  
IRL-1620 is of particular significance as it is under investigation in a number of therapeutic 
areas with efficacy demonstrated in animal models of stroke [12] and as an adjunct for 
improved delivery of chemotherapy targeting solid tumours [13].  It would therefore be of 
interest to determine the relative effect of these agonists in a number of disease relevant 
pathways, with comparison to ET-3 responses to determine evidence of bias.  These types of 
studies may highlight any differences between the agonists investigated that could be used 
either to further understand the signalling of importance to disease progression or to refine 
clinical efficacy of drugs by reducing on target detrimental effects through defined pathway 
activation. 
 
Do ET receptor antagonists show pathway bias? 
Of perhaps more consequence for the ET system is the possibility that antagonists exhibit 
pathway bias.  This has been reported for the dual ETA/ETB antagonist bosentan.  In human 
cloned receptors bosentan exhibits a modest 20 fold selectivity for the ETA receptor [14] and 
in human heart that expresses both receptor subtypes bosentan competes for the binding of 
[
125
I]ET-1 with a single affinity (KD 78nM) indicating that it does not distinguish between the 
native receptors in this tissue [15].  In human blood vessels that express predominantly ETA 
receptors bosentan exhibited, as expected, 2-20 fold higher affinity than in heart with KD of 
32nM in saphenous vein [16] and 3nM in coronary artery [17].  In contrast bosentan was a 
much less effective antagonist than would be predicted from its binding affinity in both ETA 
mediated vasoconstriction in human saphenous vein and coronary artery [15], in ETB 
mediated smooth muscle contraction [14] and ETB β-arrestin recruitment experiments [10] 
with a functional affinity of about 2μM in all these assays.  Unexpectedly, in the ETA 
mediated β-arrestin assay bosentan was 200 fold more effective an antagonist with KB of 10 
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nM [10] suggesting that bosentan is an ETA β-arrestin biased antagonist.  It is interesting to 
speculate that the relative effectiveness of bosentan in treatment of pulmonary arterial 
hypertension compared to its generally low potency as an antagonist in vitro may in part be 
explained by the greater antagonism of detrimental ETA linked β-arrestin mediated ERK1/2 
signalling [18] that could contribute to smooth muscle cell proliferation in this disease. 
 
Alternative strategies: cell penetrating peptides as biased antagonists 
Cell penetrating peptides (CPPs) are a superfamily of peptides that interact with an 
intracellular segment of a G protein coupled receptor and interfere with signalling [19].  
Pepducins – lipidated CPPs, have been developed for over 20 GPCRs including proteinase 
activated (PAR1, PAR2 and PAR4) and chemokine (CXCR1, CXCR2 and CXCR4) 
receptors.  There has been one report of a CPP, IC2B, targeting the second intracellular loop 
of the ETB receptor which has been shown to attenuate pulmonary Akt and ERK signalling 
and to blunt the development of hypoxic pulmonary hypertension in a rat in vivo model [20] 
that is thought to contribute to disease progression.  What was most interesting is that 
blockade of the ETB receptor has previously been reported to enhance development of 
pulmonary arterial hypertension in rodents suggesting that in the study by Green and 
colleagues [20] IC2B may be selectively targeting those ETB pathways contributing to 
muscularisation of the pulmonary arterial smooth muscle.  This would leave unopposed 
beneficial ETB receptor functions such as release of endothelial derived dilators, although this 
is yet to be confirmed. 
 
Clinical potential of ET receptor biased ligands 
Is there a clinical need for ET receptor biased ligands?  Evidence is strongest from research in 
epithelial ovarian cancer demonstrating that ET-1 stimulated ETA-mediated β-arrestin 
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signalling leads to activation of the oncogenic mediator NF-κB [21] and that β-arrestin-1 
epigenetically regulates ET-1-induced β-catenin signalling [22, 23] both contributing to 
tumour cell proliferation, invasion and metastasis.  A β-arrestin biased ETA antagonist would 
be predicted to have benefit over a non-biased ETA antagonist in ovarian cancer as 
ETA/Gαs/cAMP activation of protein kinase A opposes the detrimental ETA/β-arrestin 
stimulated expression of cancer genes.  ETA/Gq signalling is also oncogenic therefore an 
alternative strategy that may demonstrate even greater target refinement would be to develop 
an ETA/Gαs biased agonist as proposed by Teoh and colleagues [24] (Figure 2).  
Interestingly, pepducins have been designed for the β2-adrenoreceptor that selectively 
promote a Gαs biased conformation [25] therefore this may be one strategy that can be 
applied to biased targeting of the ETA receptor in cancer. 
 
Figure 2.  Proposed role for ET-1 activation of ETA receptors in ovarian cancer (modified 
from [24]) and potential beneficial effects of either a Gαs biased agonist or β-arrestin biased 
antagonist. 
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Could selective activation or inhibition of ET signalling pathways in heart failure result in 
clinically efficacious drugs and explain the lack of benefit of endothelin receptor antagonists 
in heart failure clinical trials to date, despite promising evidence from pre-clinical studies?  
For the angiotensin-II system it has been demonstrated that β-arrestin mediated signalling in 
heart failure is beneficial and selective activation of this pathway using TRV027 (and thus 
inhibition of G-protein signalling) promotes both vasodilatation and improved cardiac 
function at least in animal models [26].  This compound is currently being investigated in a 
Phase IIb study in patients hospitalised for acute decompensated heart failure 
(ClinialTrials.gov identifier NCT01966601) with estimated completion March 2016. 
Conversely, β-arrestin signalling in cardiac fibroblasts has been proposed to contribute to 
detrimental ventricular remodelling [27].  It is not known if ET receptor mediated β-arrestin 
signalling is protective in heart failure, but if so it could be inferred that currently available 
endothelin antagonists that block G-protein and β-arrestin signalling or bosentan that may be 
a β-arrestin biased antagonist would not produce clinical benefit and may even be 
detrimental.  However, the lack of efficacy in heart failure trials was predominantly owing to 
the development of peripheral oedema, thought to be a result of effects on endothelin 
mediated renal salt and water homeostasis rather than a lack of beneficial effect on 
haemodynamics [28].  It has also been suggested that the contribution of increased ET-1 to 
pathological cardiac remodelling in heart failure may be a result of ETA mediated inhibition 
of reuptake of noradrenaline released from cardiac sympathetic nerves [29].  Consequently 
endothelin antagonists would not confer additional advantage in patients already taking β-
blockers enrolled in these trials.  Whether the beneficial and detrimental actions of endothelin 
antagonists in heart failure or other conditions such as hypertension could be discerned by the 
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development of ligands with a particular signalling profile remains mere speculation at this 
time but should be investigated as the field matures. 
 
In summary, compared to the development and exploitation of biased ligands for other 
GPCRs the identification of compounds that selectively engage or block a subset of ET 
receptor activated signalling is only now beginning to be explored.  However, the possibility 
that the endogenous ET peptides and currently available agonists and antagonists may show 
pathway bias should be considered and investigated by all those with an interest in the role of 
the endothelin system in health and disease. 
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